NASDAQ
13.54USD
+0.01 (+0.07%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
10.8B
P/E
—
EPS
—
Beta
-1.26
52W range
12.25-30.05
Day range
13.43–13.93
Open
13.63
Prev close
13.53
Volume
2.4M
Avg volume
5.3M
Dividend
0.00
IPO
2015-03-05
https://www.barrons.com/articles/biotech-pharma-merck-novartis-bristol-myers-stocks-1b626dfc · 8/7/2026+0.50
https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-summit-therapeutics-inc-to-contact-law-firm-302834804.html · 7/27/2026-0.80
https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-sailpoint-inc-to-contact-law-firm-302834806.html · 7/27/2026-0.80
https://seekingalpha.com/article/4924370-summit-therapeutics-buy-ivonescimab-november-pdufa-and-impressive-partner-data · 7/22/2026+0.80
https://www.zacks.com/stock/news/2953710/summit-to-divest-late-stage-antibiotic-drug-to-biossil-in-105m-deal?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2953710 · 7/15/2026
https://247wallst.com/investing/2026/06/07/mizuho-strategist-healthcare-is-now-a-value-sector-as-pharma-stocks-underperform-tech/ · 6/7/2026-0.30
https://www.reuters.com/business/healthcare-pharmaceuticals/summit-rises-after-lung-cancer-drug-trial-shows-15-higher-survival-rate-than-2026-06-01/ · 6/1/2026+1.00
https://www.cnbc.com/2026/05/31/asco-summit-akeso-ivonescimab-improves-survival-in-harmoni-6-trial.html · 5/31/2026+0.60
https://www.benzinga.com/analyst-stock-ratings/initiation/26/04/51715413/summit-therapeutics-has-scarcity-value-in-a-crowded-drug-race-analyst · 4/8/2026+0.90
https://www.prnewswire.com/news-releases/akeso-reports-full-year-2025-financial-results-302726959.html · 3/27/2026+0.60
https://www.zacks.com/stock/news/2826275/fda-accepts-smmt-s-application-seeking-approval-for-nsclc-drug?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2826275 · 1/30/2026+0.60
https://www.prnewswire.com/news-releases/ivonescimab-included-in-firstword-pharmas-the-drugs-that-will-shape-2026-302673512.html · 1/29/2026+1.00
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
